Anti-Tumor Activity of PEGylated Human IL-10 (AM0010) in Patients With Pancreatic or Colorectal Cancer.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2016.34.15_suppl.3082
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Clinical Activity and Safety of Pegylated Human IL-10 (AM0010) in Combination With Anti-Pd1.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Prognostic Significance of Isolated Tumor Cells in Patients With Colorectal Cancer in Recent 10-Year Studies

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

2363 Inducing Anti-Tumor Immunity in Colorectal Cancer

Journal of Clinical and Translational Science
Medicine
2018English

IL-35 Hinders Endogenous Anti-Tumor T Cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer

Cancer immunology research
Cancer ResearchImmunology
2018English

Correlation Analysis of IL‑4, IL‑10 and APN Levels With Postoperative Infection of Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2018English

Decreased Indoleamine 2,3-Dioxygenase Activity and IL-10/IL-17A Ratio in Patients With COPD

Thorax
PulmonaryRespiratory Medicine
2012English

Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter?

Anticancer Research
MedicineCancer ResearchOncology
2016English

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

Cancer Cell
Cancer ResearchOncologyCell Biology
2018English

Anti-Tumor Activity of New Quinoline Derivatives in Human Breast Cancer T47D Cells

International Journal of Cancer Research
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy